LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "without inhibitors" as a keyword



Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial

Sign Up to like & get
recommendations! Published in 2019 at "Current Medical Research and Opinion"

DOI: 10.1080/03007995.2019.1649378

Abstract: Abstract Objectives: To compare the efficacy of emicizumab prophylaxis with that of factor VIII (FVIII) prophylaxis in patients with hemophilia A without inhibitors using two approaches: network meta-analyses (NMA) and additional sub-group analyses from the… read more here.

Keywords: hemophilia without; prophylaxis; emicizumab prophylaxis; sub ... See more keywords

Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe

Sign Up to like & get
recommendations! Published in 2022 at "Journal of Medical Economics"

DOI: 10.1080/13696998.2022.2115777

Abstract: Abstract Background and objective A cost-minimization model was developed to compare recombinant factor VIII Fc (rFVIIIFc) and emicizumab as prophylaxis for hemophilia A without inhibitors. Methods The model was based on 100 patients from the… read more here.

Keywords: recombinant factor; without inhibitors; cost; emicizumab ... See more keywords

An observational study of haemophilia A patients without inhibitors using the French national claims (SNDS) database

Sign Up to like & get
recommendations! Published in 2024 at "Hematology"

DOI: 10.1080/16078454.2024.2320610

Abstract: ABSTRACT Objectives: To describe clinical characteristics, factor consumption, and events of interest in patients with haemophilia A without inhibitors receiving prophylaxis in France, and the clinical impact of switching to Elocta® in this population. Methods:… read more here.

Keywords: consumption; observational study; without inhibitors; events interest ... See more keywords

Humanistic burden of haemophilia A without inhibitors: A cross‐sectional analysis of the HemoLIFE study

Sign Up to like & get
recommendations! Published in 2024 at "Haemophilia"

DOI: 10.1111/hae.15057

Abstract: To evaluate the impact of haemophilia A without inhibitors on humanistic outcomes in patients and caregivers. Herein, we report a cross‐sectional analysis of the baseline data of persons with haemophilia (PWH) participating in the prospective… read more here.

Keywords: without inhibitors; cross sectional; sectional analysis; haemophilia without ... See more keywords

Descriptive Characterization of Bleeding Events in Participants with Severe Hemophilia Α or B without Inhibitors, Receiving Prophylactic Marstacimab Treatment

Sign Up to like & get
recommendations! Published in 2024 at "Blood"

DOI: 10.1182/blood-2024-205975

Abstract: Background: Marstacimab is a monoclonal antibody targeted to the K2 domain of tissue factor pathway inhibitor to reduce inhibition of the extrinsic coagulation pathway and rebalance hemostasis independently of factor VIII (FVIII) and factor IX… read more here.

Keywords: month; treatment; without inhibitors; bleeding events ... See more keywords

High treatment compliance and tolerability with fitusiran antithrombin-based dose regimen in people with hemophilia A or B, with or without inhibitors: ATLAS-OLE study

Sign Up to like & get
recommendations! Published in 2025 at "Blood"

DOI: 10.1182/blood-2025-1298

Abstract: Background Hemophilia A (HB) and B (HB) are rare, inherited bleeding disorders characterized by a deficiency of clotting factors VIII or IX, respectively, leading to recurrent spontaneous and trauma-related bleeding. While prophylactic treatment with factor… read more here.

Keywords: treatment; without inhibitors; tolerability; atlas ole ... See more keywords

Management of breakthrough bleeds in participants with hemophilia Α or Β without inhibitors receiving marstacimab prophylaxis in the phase 3 BASIS study

Sign Up to like & get
recommendations! Published in 2025 at "Blood"

DOI: 10.1182/blood-2025-3066

Abstract: Background Marstacimab is a monoclonal antibody that targets the tissue factor pathway inhibitor to rebalance hemostasis. It is approved for prophylaxis in patients with hemophilia A (HA) or B (HB) without inhibitors. The pivotal phase… read more here.

Keywords: dose infusion; without inhibitors; basis; infusion ... See more keywords